Pluronic P85 enhances the efficacy of outer membrane vesicles as a subunit vaccine againstBrucella melitensischallenge in mice
Open Access
- 1 December 2012
- journal article
- Published by Oxford University Press (OUP) in FEMS Immunology & Medical Microbiology
- Vol. 66 (3) , 436-444
Abstract
Brucellosis is the most common zoonotic disease worldwide, and there is no vaccine for human use. Brucella melitensis Rev1, a live attenuated strain,Keywords
This publication has 38 references indexed in Scilit:
- What have we learned from brucellosis in the mouse model?Veterinary Research, 2012
- Serological and molecular diagnosis of human brucellosis in Najran, Southwestern Saudi ArabiaJournal of Infection and Public Health, 2012
- Characterization of Outer Membrane Vesicles fromBrucella melitensisand Protection Induced in MiceJournal of Immunology Research, 2011
- Immunization of mice with gamma-irradiated Brucella neotomae and its recombinant strains induces protection against virulent B. abortus, B. melitensis, and B. suis challengeVaccine, 2011
- Vaccine Adjuvants: Putting Innate Immunity to WorkImmunity, 2010
- Poly(Anhydride) Nanoparticles Act as Active Th1 Adjuvants through Toll-Like Receptor ExploitationClinical and Vaccine Immunology, 2010
- The effect of the nonionic block copolymer pluronic P85 on gene expression in mouse muscle and antigen-presenting cellsBiomaterials, 2009
- Pluronic block copolymers: Evolution of drug delivery concept from inert nanocarriers to biological response modifiersJournal of Controlled Release, 2008
- Pluronic® F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxinVaccine, 2007
- BrucellosisNew England Journal of Medicine, 2005